SCHEMBL23979329

SCHEMBL23979329

CS(=O)(=O)N1CCN(Cc2ccc(-c3cnc(N4CCCC4)cn3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.47
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TNF P01375 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
JAK2 O60674 1/20 0.41
JAK3 P52333 1/20 0.41
SLC16A3 O15427 1/20 0.41
MAP4K4 O95819 1/20 0.41
RECQL P46063 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LTA4H P09960 1/20 0.40
CNR2 P34972 1/20 0.40
ICAM1 P05362 1/20 0.40
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
GAA P10253 1/20 0.39
CDK6 Q00534 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21565624 0.85 HRH3 (0.53) KDM4EALDH1A1CYP2D6SLC16A3CNR2
SCHEMBL21565500 0.84 CHKA (0.54) KDM4ESLC16A3
SCHEMBL21565653 0.84 ALDH1A1 (0.47) KDM4EALDH1A1CYP2D6SLC16A3SMN1; SMN2
SCHEMBL30229943 0.84 CHKA (0.54) KDM4ESLC16A3
SCHEMBL23134819 0.84 LTA4H (0.43) KDRJAK2JAK3SLC16A3LTA4H
SCHEMBL21565727 0.84 HRH3 (0.56) KDM4EALDH1A1CYP2D6CNR2
SCHEMBL23134808 0.82 HRH3 (0.62) KDRALDH1A1SLC16A3MAP4K4OPRM1
SCHEMBL21565608 0.81 CNR2 (0.41) ALDH1A1CYP2D6SLC16A3CNR2OPRM1
SCHEMBL21565737 0.81 CHKA (0.60) KDM4ESLC16A3
SCHEMBL21565532 0.81 CASP1 (0.42) ALDH1A1CYP2D6SLC16A3CNR2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
US-20210340150-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340150-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 KDR 144/4885KDM4E 1071/4885ALDH1A1 205/4885
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 KDR 144/4885KDM4E 1071/4885ALDH1A1 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.